Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance

PHASE3CompletedINTERVENTIONAL
Enrollment

557

Participants

Timeline

Start Date

June 26, 2018

Primary Completion Date

July 2, 2019

Study Completion Date

July 2, 2019

Conditions
Lactose Intolerance
Interventions
DRUG

RP-G28

powder for reconstitution for oral administration

DRUG

Placebos

powder for reconstitution for oral administration

Trial Locations (35)

10530

Research Site, Hartsdale

11023

Research Site, Great Neck

11230

Research Site, Brooklyn

20745

Research Site, Oxon Hill

22031

Research Site, Fairfax

27612

Research Site, Raleigh

29406

Research Site, Charleston

32653

Research Site, Gainesville

32806

Research Site, Orlando

33060

Reseaarch Site, Pompano Beach

33135

Research Facility, Miami

35205

Research Facility, Birmingham

37909

Research Site, Knoxville

45246

Research Site, Cincinnati

45439

Research Site, Dayton

49519

Research Site, Wyoming

68114

Research Site, Omaha

70072

Research Site, Marrero

75165

Research Site, Waxahachie

76550

Research Site, Lampasas

77099

Research Site, Houston

78209

Research Site, San Antonio

80906

Research Site, Colorado Springs

87102

Research Site, Albuquerque

90057

Research Site, Los Angeles

90255

Research Site, Huntington Park

91402

Research Site, Panorama City

91910

Research Site, Chula Vista

92114

Research Site, San Diego

92123

Research Site, San Diego

94598

Research Site, Walnut Creek

95648

Research Site, Lincoln

96815

Research Site, Honolulu

98004

Research Site, Bellevue

08009

Research Site, Berlin

All Listed Sponsors
lead

Ritter Pharmaceuticals, Inc.

INDUSTRY

NCT03597516 - Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance | Biotech Hunter | Biotech Hunter